Ten case studies from Auperon's platform work across cell & gene therapy, mammalian bioprocessing, microbial fermentation, recombinant protein, chemically-defined media, and novel biology. Different customers, different questions — same mechanism-level approach.
"How do we optimize our prototype iPSC media to outperform commercial standards — and yield higher-quality target stem cell populations when we later trigger differentiation?"
Why this matters. Generating transplantable target stem cell populations from iPSCs remains one of the biggest unsolved problems in regenerative medicine — every mechanism-level optimization at the pre-differentiation stage compounds into the final yield when differentiation is eventually triggered.
Customer: A leading commercial supplier of human cell products for regenerative medicine and cell therapy applications (repeat Auperon customer).
"How do we optimize TIL differentiation and shorten our expansion protocol — without sacrificing therapeutic potential — for precision cancer treatment?"
Why this matters. The FDA's 2024 approval of lifileucel (Amtagvi) — the first cellular therapy approved for any solid tumor — validated TIL therapy for advanced melanoma and opened a path forward for other cancers. But the field faces a persistent tension: shorter expansion protocols mean faster patient access and lower manufacturing costs, while longer protocols risk immune exhaustion, dysfunction, and reduced therapeutic potency. Every day cut from a 22-day manufacturing process is meaningful — for cost, for patient wait time, and for the population of patients TIL therapy can practically reach.
Customer: A leading cell therapy manufacturing center advancing TIL therapy for solid tumor indications. Commercial partner name protected under confidentiality.
"How can multi-omic analysis identify novel media additive candidates that improve viability, expansion, and FOXP3 stability for a cGMP Treg expansion protocol for autologous ulcerative colitis therapy?"
Why this matters. Ulcerative colitis affects millions with debilitating chronic inflammation. Autologous Treg cell therapy represents a promising alternative to lifelong immunosuppression — but the inflammatory milieu of UC specifically downregulates FOXP3 expression, causing Tregs to transdifferentiate into pro-inflammatory effector T cells. Manufacturing a Treg product that maintains stability and function in the gut environment is one of the field's central technical challenges.
Study type: BD-driven Auperon Tier 2 workflow — we ran this analysis on our own capital to demonstrate what mechanism-level insight could contribute to leading Treg cell therapy programs pursuing UC-specific applications.
"How do we optimize our chemically-defined MSC media to match the performance of our serum-containing formulation — and eliminate particular stress phenotypes in a variant showing this issue?"
Why this matters. MSC therapies span 850+ clinical trials in regenerative medicine, but the industry's shift from serum-containing to chemically-defined media especially for 3D culture, remains a critical bottleneck for clinical translation and cost — and figuring out what serum was actually providing that CDM lacked is a mechanism-level question, not an empirical screening one.
Customer: A leading commercial supplier of human MSCs for cell therapy applications.
"Can Auperon's platform surface actionable insights on our novel cell culture system — and identify where to focus optimization to reduce culture variability, extend viable culture duration, and improve developmental outcomes?"
Why this matters. Stem-cell-derived embryo models are opening new territory in developmental biology, disease modeling, and regenerative medicine — but variability in starting material, viable culture duration, and reproducibility remain fundamental barriers to broader use.
Customer: A pioneering biotech developing next-generation stem cell platforms for regenerative medicine.
Initial: "Can we identify targets that would improve T cell / Treg manufacturing from public data alone?"
Sharpened: "Can we surface novel FOXP3 regulators and growth factor candidates as viable media additives?"
Why this matters. Regulatory T cell therapies represent a fast-growing frontier — the market is projected to grow from $22M in 2025 to $442M by 2035 across autoimmune diseases, transplant rejection, and inflammatory conditions. With 69+ active Treg clinical trials and 90+ companies pursuing this modality, the central manufacturing challenge is well-known: FOXP3 stability. Induced Tregs readily lose FOXP3 expression and revert to conventional T effector cells. Ex vivo expanded Tregs show poor survival post-transfer. Standard expansion protocols yield highly variable fold expansion. The field needs better media.
Study type: Public dataset study demonstrating Auperon Tier 1 workflow.
"How do we design a chemically-defined culture supplement that outperforms serum for HEK-based recombinant protein and vaccine antigen production — and prove it scales beyond a single cell line?"
Why this matters. HEK293 remains the workhorse for viral vector, vaccine antigen (RBD, spike proteins), and recombinant protein production. But serum dependency is a persistent scaling and cost bottleneck — batch variability, supply constraints, regulatory friction. Designing a chemically-defined supplement that matches or beats serum performance is a mechanism-level problem, not a formulation screening one.
Completed in partnership with Foresight Biosciences.
"Can we materially boost recombinant protein titer in E. coli — for both structural proteins and reporter cassettes — without re-engineering the strain, vector, or induction system?"
Why this matters. E. coli remains the highest-throughput host for recombinant protein production — from pharma-grade collagen to research reagents to vaccine antigens. Titer optimization traditionally means costly strain engineering, cassette redesign, or extensive fermentation DoE. A supplement-only intervention that drives 3–5X titer improvement without touching the biology bypasses months of downstream work.
Completed in partnership with UTMB Health (recombinant collagen study).
"Can we design a chemically-defined culture medium and a universal fermentation additive that consistently outperforms LB across E. coli variants, bacterial species, and third-party validation?"
Why this matters. LB broth is a black box. It works because it works — but its undefined composition creates lot-to-lot variability, complicates regulatory paths for GMP-adjacent applications, and blocks systematic optimization. A chemically-defined replacement AND a universal additive that improves fermentation across strains would collapse cost, variability, and time-to-scale simultaneously.
Multi-partner engagement including third-party validation by Ourobio and Arzeda. Individual programs remain under confidentiality.
"Can we design a chemically-defined, serum-free supplement that matches or exceeds FBS performance for primary mouse myoblasts?"
Why this matters. The cultured meat industry's economic viability depends on replacing FBS. Fetal bovine serum is expensive, supply-constrained, undefined, and philosophically incompatible with the product it's used to produce. Mouse myoblasts serve as an accessible model system for developing and validating serum-free formulations before moving to production cell lines. But primary muscle cell performance in serum-free media has historically fallen short on both growth rate and morphology. A defined replacement that hits both metrics unlocks the next stage of formulation work.
Cultured meat program (commercial partner protected under confidentiality).
Fixed scope. Fixed price. Fixed timeline. Discovery starts at $9,900.